Bicycle Therapeutics plc (NASDAQ:BCYC) Receives Consensus Rating of “Moderate Buy” from Brokerages

Bicycle Therapeutics plc (NASDAQ:BCYC) has earned a consensus rating of “Moderate Buy” from the seven analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $46.86.

A number of brokerages have recently weighed in on BCYC. Canaccord Genuity Group reaffirmed a “buy” rating and set a $60.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday, February 21st. Needham & Company LLC reissued a “buy” rating and set a $43.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday, April 10th. Finally, HC Wainwright restated a “buy” rating and issued a $55.00 target price on shares of Bicycle Therapeutics in a report on Friday, May 3rd.

Insider Buying and Selling at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,158 shares of Bicycle Therapeutics stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $23.81, for a total transaction of $75,191.98. Following the completion of the transaction, the chief executive officer now owns 387,270 shares in the company, valued at approximately $9,220,898.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 5,312 shares of company stock worth $126,139. Insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On Bicycle Therapeutics

Hedge funds have recently modified their holdings of the company. BluePath Capital Management LLC bought a new position in shares of Bicycle Therapeutics during the 3rd quarter worth approximately $31,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Bicycle Therapeutics by 489.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,001 shares of the company’s stock worth $72,000 after buying an additional 3,322 shares in the last quarter. Exchange Traded Concepts LLC lifted its position in shares of Bicycle Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 6,727 shares of the company’s stock worth $122,000 after buying an additional 1,706 shares in the last quarter. PNC Financial Services Group Inc. bought a new position in shares of Bicycle Therapeutics during the 4th quarter worth approximately $137,000. Finally, PDS Planning Inc bought a new position in shares of Bicycle Therapeutics during the 1st quarter worth approximately $210,000. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Trading Down 0.2 %

NASDAQ:BCYC opened at $23.58 on Friday. The firm has a fifty day simple moving average of $23.84 and a two-hundred day simple moving average of $19.63. Bicycle Therapeutics has a 12 month low of $12.54 and a 12 month high of $28.91. The stock has a market capitalization of $708.41 million, a price-to-earnings ratio of -5.30 and a beta of 0.90. The company has a current ratio of 10.42, a quick ratio of 10.42 and a debt-to-equity ratio of 0.09.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Thursday, May 2nd. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($1.25) by $0.63. Bicycle Therapeutics had a negative return on equity of 49.35% and a negative net margin of 404.14%. The company had revenue of $19.53 million during the quarter, compared to the consensus estimate of $6.06 million. Bicycle Therapeutics’s quarterly revenue was up 298.9% on a year-over-year basis. Analysts expect that Bicycle Therapeutics will post -5.13 EPS for the current fiscal year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.